Penumbra Inc (PEN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Penumbra Inc stock (PEN) is currently trading at $336.27. Penumbra Inc PE ratio is 74.10. Penumbra Inc PS ratio (Price-to-Sales) is 9.34. Analyst consensus price target for PEN is $360.13. WallStSmart rates PEN as Hold.
- PEN PE ratio analysis and historical PE chart
- PEN PS ratio (Price-to-Sales) history and trend
- PEN intrinsic value — DCF, Graham Number, EPV models
- PEN stock price prediction 2025 2026 2027 2028 2029 2030
- PEN fair value vs current price
- PEN insider transactions and insider buying
- Is PEN undervalued or overvalued?
- Penumbra Inc financial analysis — revenue, earnings, cash flow
- PEN Piotroski F-Score and Altman Z-Score
- PEN analyst price target and Smart Rating
Penumbra Inc
📊 No data available
Try selecting a different time range
PEN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Penumbra Inc (PEN)
PEN trades 60% above its Graham fair value of $211.07, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Penumbra Inc (PEN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, revenue growth. Concerns around price/sales and price/book. Fundamentals are solid but monitor weak areas for improvement.
Penumbra Inc (PEN) Key Strengths (5)
Growing significantly faster than its price suggests
Earnings per share surging 38.30% year-over-year
95.54% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong revenue growth at 22.10% annually
Penumbra Inc (PEN) Areas to Watch (5)
Very expensive at 9.3x annual revenue
Very expensive at 9.2x book value
Moderate profitability with room for improvement
Decent operational efficiency, solid but not exceptional
Decent profitability, keeps $13 per $100 revenue
Supporting Valuation Data
Penumbra Inc (PEN) Detailed Analysis Report
Overall Assessment
This company scores 64/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.4/10) while 5 fall into concern territory (avg 4.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, EPS Growth, Institutional Own.. Valuation metrics including PEG Ratio (0.76) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 22.10%, EPS Growth at 38.30%.
The Bear Case
The primary concerns are Price/Sales, Price/Book, Return on Equity. Some valuation metrics including Price/Sales (9.34), Price/Book (9.19) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 13.80%, Operating Margin at 15.40%, Profit Margin at 12.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 13.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 22.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, EPS Growth) and negatives (Price/Sales, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PEN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PEN's Price-to-Sales ratio of 9.34x trades 24% below its historical average of 12.36x (21th percentile). The current valuation is 56% below its historical high of 21.42x set in Apr 2021, and 41% above its historical low of 6.61x in Jul 2024.
WallStSmart Analysis Synopsis
Data-driven financial summary for Penumbra Inc (PEN) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Penumbra Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 1.4B with 22% growth year-over-year. Profit margins of 12.7% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 1380.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 68M in free cash flow and 86M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Penumbra Inc push profit margins above 15% as the business scales?
Growth sustainability: can Penumbra Inc maintain 22%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 74.1x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Penumbra Inc.
Bottom Line
Penumbra Inc offers an attractive blend of growth (22% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Penumbra Inc(PEN)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company is headquartered in Alameda, California.